[Prophylaxis and differential therapy of tumorlysis syndrome]

Dtsch Med Wochenschr. 2004 Jun 18;129(25-26):1440-5. doi: 10.1055/s-2004-826887.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Allopurinol / therapeutic use
  • Antimetabolites / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Cost-Benefit Analysis
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Neoplasms / drug therapy*
  • Risk Factors
  • Tumor Lysis Syndrome / economics
  • Tumor Lysis Syndrome / etiology*
  • Tumor Lysis Syndrome / prevention & control
  • Urate Oxidase / economics
  • Urate Oxidase / therapeutic use
  • Uric Acid / metabolism
  • Water-Electrolyte Balance

Substances

  • Antimetabolites
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • rasburicase
  • Uric Acid
  • Allopurinol
  • Urate Oxidase